The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies

References

• Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8(6):468–10. doi:10.1016/S2213-8587(20)30115-7.
   PubMed Web of Science ®Google Scholar
• Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–660. doi:10.1038/nrendo.2017.76.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17–44. doi:10.1677/ERC-08-0154.
   PubMed Web of Science ®Google Scholar
• Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2017;8:312. doi:10.3389/fendo.2017.00312.
   PubMed Web of Science ®Google Scholar
• Bernet V, Smallridge R. New therapeutic options for advanced forms of thyroid cancer. Expert Opin Emerg Drugs. 2014;19(2):225–241. doi:10.1517/14728214.2014.894017.
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638–2648. doi:10.1002/(SICI)1097-0142(19981215)83:12<2638:AID-CNCR31>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Fagin JA, Wells SA Jr., Longo DL. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–1067. doi:10.1056/NEJMc1613118.
   PubMed Web of Science ®Google Scholar
• Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008;26(29):4701–4704. doi:10.1200/JCO.2008.17.3682.
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–199. doi:10.1038/nrc3431.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. doi:10.1056/NEJMoa1103782.
   PubMed Web of Science ®Google Scholar
• Brose MS, Cabanillas ME, Cohen EEW, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(9):1272–1282. doi:10.1016/S1470-2045(16)30166-8.
   PubMed Web of Science ®Google Scholar
• Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, et al. Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18(7):2056–2065. doi:10.1158/1078-0432.CCR-11-0563.
   PubMed Web of Science ®Google Scholar
• Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid. 2018;28(1):79–87. doi:10.1089/thy.2017.0285.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. doi:10.1200/JCO.2017.73.6785.
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–972. doi:10.1038/nature09627.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–390. doi:10.1038/nature10662.
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93. doi:10.1158/2159-8290.CD-13-0642.
   PubMed Web of Science ®Google Scholar
• Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767–1774. doi:10.1200/JCO.2012.44.7888.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683–695. doi:10.1016/j.ccr.2010.11.023.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260. doi:10.1016/S1470-2045(16)30122-X.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob J-J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451. doi:10.1016/S0140-6736(15)60898-4.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39. doi:10.1056/NEJMoa1412690.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406–415. doi:10.1016/j.annonc.2021.12.014.
   PubMed Web of Science ®Google Scholar
• Shah MH, Wei L, Wirth LJ, Daniels GA, De Souza JA, Timmers CD, Sexton JL, Beshara M, Nichols D, Snyder N, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol. 2017;35(15_suppl):6022–6022. doi:10.1200/JCO.2017.35.15_suppl.6022.
   Google Scholar
• Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding aurora-B through mitosis. J Cell Biol. 2006;173(6):833–837. doi:10.1083/jcb.200604032.
   PubMed Web of Science ®Google Scholar
• Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937–23954. doi:10.18632/oncotarget.14893.
   PubMedGoogle Scholar
• Zhao ZW, Wang H, Kang N, Wang Z, Hou X, Hu L, Qie S, Guo J, Wei S, Ruan X et al. Aurora kinase a promotes the progression of papillary thyroid carcinoma by activating the mTORC2-AKT signalling pathway. Cell Biosci 12 (2022):ARTN 19510.1186/s13578-022-00934-z
   Google Scholar
• Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, et al. Establishment and Characterization of four Novel Thyroid cancer Cell Lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Mol Cancer Res. 2019;17(5):1036–1048. doi:10.1158/1541-7786.MCR-18-1026.
   PubMed Web of Science ®Google Scholar
• Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, et al. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin Cancer Res. 2019;25(10):3141–3151. doi:10.1158/1078-0432.CCR-18-2953.
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93(11):4331–4341. doi:10.1210/jc.2008-1102.
   PubMed Web of Science ®Google Scholar
• Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, Schweppe ER, et al. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021;60(3):201–212. doi:10.1002/mc.23284.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi:10.1016/0065-2571(84)90007-4.
   PubMedGoogle Scholar
• Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D’Angelo C, Petrucci MT, et al. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007;109(5):2121–2129. doi:10.1182/blood-2006-05-024679.
   PubMed Web of Science ®Google Scholar
• Byeon HK, Na HJ, Yang YJ, Ko S, Yoon SO, Ku M, Yang J, Kim JW, Ban MJ, Kim J-H, et al. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-met-mediated AKT activation. Oncotarget. 2017;8(1):596–609. doi:10.18632/oncotarget.13480.
   PubMedGoogle Scholar
• Byeon HK, Na HJ, Yang YJ, Kwon HJ, Chang JW, Ban MJ, Kim WS, Shin DY, Lee EJ, Koh YW, et al. C-met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Mol Carcinog. 2016;55(11):1678–1687. doi:10.1002/mc.22418.
   PubMed Web of Science ®Google Scholar
• Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009;94(10):4107–4112. doi:10.1210/jc.2009-0662.
   PubMed Web of Science ®Google Scholar
• Torre D, Lachmann A, Ma’ayan A. BioJupies: automated generation of Interactive Notebooks for RNA-Seq Data Analysis in the cloud. Cell Syst. 2018;7(5):556–561.e3. doi:10.1016/j.cels.2018.10.007.
   PubMed Web of Science ®Google Scholar
• Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3(7):742–750. doi:10.1158/2159-8290.CD-13-0070.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Liu B, O’Brien C, Spoerke JM, Hoeflich KP, Haverty PM, Soriano R, Forrest WF, Heldens S, Chen H, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012;11(5):1143–1154. doi:10.1158/1535-7163.MCT-11-1010.
   PubMed Web of Science ®Google Scholar
• Li Y, Li X, Pu J, Yang Q, Guan H, Ji M, Shi B, Chen M, Hou P. C-myc is a Major determinant for antitumor activity of Aurora a kinase inhibitor MLN8237 in thyroid cancer. Thyroid. 2018;28(12):1642–1654. doi:10.1089/thy.2018.0183.
   PubMed Web of Science ®Google Scholar
• Zhang W, Pear WS. MYC degradation via AURKB inhibition: a new brake in the path to T-ALL. Blood Sci. 2020;2(2):68–69. doi:10.1097/BS9.0000000000000046.
   PubMedGoogle Scholar
• Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, et al. Small molecule inhibitors of aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma. Cancer Cell. 2016;30(2):357–358. doi:10.1016/j.ccell.2016.07.002.
   PubMed Web of Science ®Google Scholar
• Lake D, Correa SA, Muller J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci. 2016;73(23):4397–4413. doi:10.1007/s00018-016-2297-8.
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–U370. doi:10.1038/nature09627.
   PubMed Web of Science ®Google Scholar
• Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles’ heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica B. 2018;8(4):552–562. doi:10.1016/j.apsb.2018.01.008.
   PubMed Web of Science ®Google Scholar
• Jiang J, Wang J, Yue M, Cai X, Wang T, Wu C, Su H, Wang Y, Han M, Zhang Y, et al. Direct phosphorylation and stabilization of MYC by aurora B kinase promote T-cell leukemogenesis. Cancer Cell. 2020;37(2):200–215.e5. doi:10.1016/j.ccell.2020.01.001.
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Linardopoulos S. Aurora Kinase Inhibitors: Current Status and Outlook. Front Oncol. 2015;5:278. doi:10.3389/fonc.2015.00278.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, Zheng Q, Cai C. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11(5):1913–1935.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, Spira AI, Tsai ML, Samuëlsz E, Silberman SL, et al. A phase ib study of Onvansertib, a Novel Oral PLK1 Inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2020;26(23):6132–6140. doi:10.1158/1078-0432.CCR-20-2586.
   PubMed Web of Science ®Google Scholar
• Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012;3(10):1112–1123. doi:10.18632/oncotarget.604.
   PubMedGoogle Scholar
• Rapino F, Naumann I, Fulda S. Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death Disease. 2013;4(11):e925. doi:10.1038/cddis.2013.440.
   PubMedGoogle Scholar
• Lin SF, Lin J-D, Yeh C-N, Huang Y-T, Chou T-C, Wong RJ. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Endocr-Relat Cancer. 2019;26(8):727–738. doi:10.1530/ERC-18-0555.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66(2):105–143. doi:10.1016/j.phrs.2012.04.005.
   PubMed Web of Science ®Google Scholar
• Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma’ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics. 2010;26(19):2438–2444. doi:10.1093/bioinformatics/btq466.
   PubMed Web of Science ®Google Scholar
• Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann M-C, McKenna LR, Schweppe RE. Fibronectin contributes to a BRAF Inhibitor–driven invasive phenotype in thyroid cancer through EGR1, which can Be blocked by inhibition of ERK1/2. Mol Cancer Res. 2023;21(9):867–880. doi:10.1158/1541-7786.MCR-22-1031.
   PubMed Web of Science ®Google Scholar
• Gully CP, Velazquez-Torres G, Shin J-H, Fuentes-Mattei E, Wang E, Carlock C, Chen J, Rothenberg D, Adams HP, Choi HH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A. 2012;109(24):E1513–1522. doi:10.1073/pnas.1110287109.
   PubMed Web of Science ®Google Scholar
• Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann M-C, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 induction mediates sensitivity to src and MEK1/2 inhibition in thyroid cancer. Cancers Basel. 2023;15(2):378. doi:10.3390/cancers15020378.
   PubMed Web of Science ®Google Scholar